Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

41. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial (Abstract)

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus (...) lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.LixiLan-G, a randomized, open-label, 26-week trial, compared switching to iGlarLixi versus continuing prior GLP-1 RA in patients with type 2 diabetes and HbA1c 7-9% (53-75 mmol/mol) taking maximum tolerated doses of a GLP-1 RA daily (60% on liraglutide once daily or exenatide twice daily) or weekly (40% on dulaglutide, exenatide extended release, or albiglutide) with metformin with or without pioglitazone

2019 EvidenceUpdates

42. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial Full Text available with Trip Pro

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor antagonist, could improve both glycaemic and inflammatory

2019 EvidenceUpdates

43. Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled trial Full Text available with Trip Pro

Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled trial To assess whether the regular intake of an oleanolic acid (OA)-enriched olive oil is effective in the prevention of diabetes.In the PREDIABOLE study, prediabetic individuals (impaired fasting glucose and impaired glucose tolerance) of both sexes (176 patients, aged 30-80 years) were randomized to receive 55 mL/day of OA-enriched (...) olive oil (equivalent dose 30 mg OA/day) [intervention group (IG)] or the same oil not enriched [control group (CG)]. The main outcome was the incidence of new-onset type 2 diabetes in both groups.Forty-eight new diabetes cases occurred, 31 in the CG and 17 in the IG. The multivariate-adjusted hazard ratio was 0.45 (95% CI, 0.24-0.83) for the IG compared with the CG. Intervention-related adverse effects were not reported.The intake of OA-enriched olive oil reduces the risk of developing diabetes

2019 EvidenceUpdates

44. To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. In the United States, 9.4% of all adults-and 25% of those older than 65 years-have diabetes. Diabetes is the leading cause of blindness and end-stage renal disease and contributes to both microvascular and macrovascular complications. The management of patients with type 2 diabetes (T2D) is a common and important activity in primary care (...) proposed a level between 7% and 8% for most patients. The ACP also advised deintensification of therapy for patients who have an HbA1c level lower than 6.5% and avoidance of HbA1c-targeted treatment for patients with a life expectancy of less than 10 years. This guidance contrasts with a recommendation from the American Diabetes Association to aim for HbA1c levels less than 7% for many nonpregnant adults and to consider a target of 6.5% if it can be achieved safely. Here, 2 experts, a diabetologist

2019 Annals of Internal Medicine

45. Cardiovascular Outcome Trials for Type 2 Diabetes

Cardiovascular Outcome Trials for Type 2 Diabetes Cardiovascular Outcome Trials for Type 2 Diabetes | CADTH.ca CADTH Document Viewer Cardiovascular Outcome Trials for Type 2 Diabetes Table of Contents Search this document Cardiovascular Outcome Trials for Type 2 Diabetes June 2019 Summary Dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists are classes of medications used in diabetes mellitus (DM (...) ) to improve glycemic control in people with type 2 diabetes mellitus (T2DM). Evidence from cardiovascular outcome trials (CVOT) is available for a number of medications; CVOTs are still in progress or have yet to be published for some others. The trials examined the addition of the medication in question to standard of care compared with placebo in patients with T2DM and established cardiovascular disease (CVD) or patients who are at high risk of cardiovascular (CV) events.The outcome measured

2019 CADTH - Issues in Emerging Health Technologies

46. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review

REPORTING ON LIFE EXPECTANCY 15 3.2.1. Literature search 15 3.2.2. The Scottish registry-based cohort study by Livingstone et al. 15 3.2.3. The Swedish registry-based cohort study by Petrie et al 16 2 Excess mortality and life expectancy of individuals with type 1 diabetes KCE Report 314 3.2.4. The Australian registry-based cohort study by Huo et al.. 16 3.2.5. Consistency of the evidence in the Scottish, Swedish and Australian cohort studies 17 3.2.6. The Taiwanese longitudinal cohort study based (...) 6 Excess mortality and life expectancy of individuals with type 1 diabetes KCE Report 314 PAD Peripheral Artery Disease PICO(D) Patient, Intervention, Comparator, Outcome, (Design) PY, PYE Patient Years (of Exposure or follow-up): PY or PYE can be used interchangeably RF Risk Factor(s) RR Relative Risk SMR Standardized Mortality Ratio SR Systematic Review T1D Type 1 Diabetes T2D Type 2 Diabetes y Year YLL Years of Life Lost KCE Report 314 Excess mortality and life expectancy of individuals

2019 Belgian Health Care Knowledge Centre

47. Use of SGLT-2 inhibitors in the treatment of diabetes Full Text available with Trip Pro

Use of SGLT-2 inhibitors in the treatment of diabetes Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019) | Dashora | British Journal of Diabetes Font Size User Username Password Remember me Click for EXTOD PEAK 2019 Conference 18th October 2019, Glasgow ABCD Autumn Meeting 2019 28 / 29 November 2019, London All issues 2014-present Browse Search All issues from 2014 Refine 2001-2013 (...) at OR View listing of all 2001-2013 issues . Click on the issue you want to view it at About The Authors Umesh Dashora East Sussex Healthcare NHS Trust Dipesh C Patel Robert Gregory Peter Winocour Ketan Dhatariya Dinesh Nagi Hosted By Part of the > > Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019) Umesh Dashora, Dipesh C Patel, Robert Gregory, Peter Winocour, Ketan Dhatariya, Dinesh Nagi

2019 Association of British Clinical Diabetologists

48. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Full Text available with Trip Pro

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic (...) in urinary albumin excretion. There was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer.Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes.None.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 EvidenceUpdates

49. Drugs for Type 2 Diabetes: Second-Line Therapy Review Update

Drugs for Type 2 Diabetes: Second-Line Therapy Review Update Drugs for Type 2 Diabetes: Second-Line Therapy Review Update | CADTH.ca Find the information you need Drugs for Type 2 Diabetes: Second-Line Therapy Review Update Drugs for Type 2 Diabetes: Second-Line Therapy Review Update Published on: February 7, 2018 Project Number: TR0012-000 Product Line: Therapeutic Review Result type: Report For an update on the status of CADTH’s Therapeutic Review of Third-Line Drugs for Type 2 Diabetes (...) , please . CADTH undertook a project to assess the clinical and cost-effectiveness of new drugs for the treatment of patients with type 2 diabetes. These new drugs were in three classes: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. As part of this project, recommendations from the CADTH Canadian Drug Expert Committee (CDEC) were developed. This project is an update to two large projects on pharmacotherapy

2019 CADTH - Therapeutic Review

50. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. (Abstract)

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator.This trial assessed cardiovascular outcomes of linagliptin vs glimepiride (sulfonylurea (...) ) in patients with relatively early type 2 diabetes and risk factors for or established atherosclerotic cardiovascular disease.Randomized, double-blind, active-controlled, noninferiority trial, with participant screening from November 2010 to December 2012, conducted at 607 hospital and primary care sites in 43 countries involving 6042 participants. Adults with type 2 diabetes, glycated hemoglobin of 6.5% to 8.5%, and elevated cardiovascular risk were eligible for inclusion. Elevated cardiovascular risk

2019 JAMA

51. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. (Abstract)

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy has been suggested to offer more opportunities than a traditional stepwise approach, its validity remains (...) to be determined.Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes (VERIFY) was a randomised, double-blind, parallel-group study of newly diagnosed patients with type 2 diabetes conducted in 254 centres across 34 countries. The study consisted of a 2-week screening visit, a 3-week metformin-alone run-in period, and a 5-year treatment period, which was further split into study periods 1, 2, and 3. Patients aged 18-70 years were included if they had type 2 diabetes diagnosed within 2

2019 Lancet

52. Trends in incidence of total or type 2 diabetes: systematic review. Full Text available with Trip Pro

Trends in incidence of total or type 2 diabetes: systematic review. To assess what proportions of studies reported increasing, stable, or declining trends in the incidence of diagnosed diabetes.Systematic review of studies reporting trends of diabetes incidence in adults from 1980 to 2017 according to PRISMA guidelines.Medline, Embase, CINAHL, and reference lists of relevant publications.Studies of open population based cohorts, diabetes registries, and administrative and health insurance (...) databases on secular trends in the incidence of total diabetes or type 2 diabetes in adults were included. Poisson regression was used to model data by age group and year.Among the 22 833 screened abstracts, 47 studies were included, providing data on 121 separate sex specific or ethnicity specific populations; 42 (89%) of the included studies reported on diagnosed diabetes. In 1960-89, 36% (8/22) of the populations studied had increasing trends in incidence of diabetes, 55% (12/22) had stable trends

2019 BMJ

53. Postprandial metabolic effects of fructose and glucose in type 1 diabetes patients: a pilot randomized crossover clinical trial. Full Text available with Trip Pro

Postprandial metabolic effects of fructose and glucose in type 1 diabetes patients: a pilot randomized crossover clinical trial. To test the influence of oral fructose and glucose dose-response solutions in blood glucose (BG), glucagon, triglycerides, uricaemia, and malondialdehyde in postprandial states in type 1 diabetes mellitus (T1DM) patients.The study had a simple-blind, randomized, two-way crossover design in which T1DM patients were selected to receive fructose and glucose solutions (...) (75g of sugars dissolved in 200 mL of mineral-water) in two separate study days, with 2-7 weeks washout period. In each day, blood samples were drawn after 8h fasting and at 180 min postprandial to obtain glucose, glucagon, triglycerides, uric acid, lactate, and malondialdehyde levels.Sixteen T1DM patients (seven men) were evaluated, with a mean age of 25.19 ± 8.8 years, a mean duration of disease of 14.88 ± 4.73 years, and glycated hemoglobin of 8.13 ± 1.84%. Fructose resulted in lower

2019 Archives of endocrinology and metabolism Controlled trial quality: uncertain

54. Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. Full Text available with Trip Pro

Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. Although metabolic surgery (defined as procedures that influence metabolism by inducing weight loss and altering gastrointestinal physiology) significantly improves cardiometabolic risk factors, the effect on cardiovascular outcomes has been less well characterized.To investigate the relationship between metabolic surgery and incident major adverse cardiovascular events (...) (MACE) in patients with type 2 diabetes and obesity.Of 287 438 adult patients with diabetes in the Cleveland Clinic Health System in the United States between 1998 and 2017, 2287 patients underwent metabolic surgery. In this retrospective cohort study, these patients were matched 1:5 to nonsurgical patients with diabetes and obesity (body mass index [BMI] ≥30), resulting in 11 435 control patients, with follow-up through December 2018.Metabolic gastrointestinal surgical procedures vs usual care

2019 JAMA

55. Dapagliflozin (Forxiga) - type 1 diabetes mellitus

, Albers JW, Pop-Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2013;37(1):31-8. Epub 12/21. 12. Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2014;64(2):631-42. Epub 09/11. 13. de Boer IH. Kidney (...) . Indication under review: In adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI =27kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. Dapagliflozin in combination with insulin improved glycaemic control compared with insulin alone in adult patients with inadequately controlled type 1 diabetes. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication

2019 Scottish Medicines Consortium

56. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Full Text available with Trip Pro

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention).In CREDENCE (Canagliflozin and Renal Events in Diabetes (...) With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care.Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk

2019 EvidenceUpdates

57. Dapagliflozin with insulin for treating type 1 diabetes

. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dapagliflozin with insulin for treating type 1 diabetes (TA597) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1 Recommendations 4 2 Information about dapagliflozin 6 3 (...) for treating type 1 diabetes (TA597) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 241 1 Recommendations Recommendations 1.1 Dapagliflozin with insulin is recommended as an option for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, only if: they are on insulin doses of more than 0.5

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

58. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials (Abstract)

GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials A meta-analysis of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RAs) and placebo concerning cardiorenal outcomes in patients with type 2 diabetes (T2D) is presented. An electronic search without language restrictions up to June 15, 2019 was conducted to determine eligible trials. A meta-analysis (...) the progression of diabetic renal disease.© 2019 John Wiley & Sons Ltd.

2019 EvidenceUpdates

59. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial (Abstract)

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial To assess the addition of linagliptin as an alternative to insulin uptitration in older people with type 2 diabetes on stable insulin therapy.This phase 4, randomized, multicentre, double-blinded, placebo-controlled, 24-week study recruited individuals on stable insulin, with baseline HbA1c 7.0%-10.0%, aged ≥60 years and body mass index ≤45 kg/m2 (...) , including clinically important hypoglycaemia (blood glucose <54 mg/dL) or severe hypoglycaemia.Addition of linagliptin improves glucose control without an excess of hypoglycaemia in older patients with type 2 diabetes on stable insulin therapy.© 2019 John Wiley & Sons Ltd.

2019 EvidenceUpdates

60. An evidence-based approach to developing low-carbohydrate diets for type 2 diabetes management: A systematic review of interventions and methods Full Text available with Trip Pro

An evidence-based approach to developing low-carbohydrate diets for type 2 diabetes management: A systematic review of interventions and methods To identify core diet and delivery components of low-carbohydrate (CHO) diets that have demonstrated efficacy for type 2 diabetes (T2D) management.MEDLINE, Pre-MEDLINE, EMBASE, CINAHL and the Cochrane Library of Controlled Trials databases were systematically searched from inception until August 18, 2018. Primary intervention studies of low-CHO diets (...) . Thirty-one studies reported a total energy prescription, of which 18/31 encouraged ad libitum intakes. Twenty studies reported a prescribed dietary fat amount, of which 18/20 were unrestricted or high-fat (>35% TEI). Twenty-six studies reported a prescribed dietary protein amount, of which 22 were unrestricted or were high-protein (>25% TEI). The types of dietary CHO, fat and protein recommended were predominantly whole foods. Common delivery methods reported were dietician and/or physician

2019 EvidenceUpdates